Julianne Bruno
Fortune : 5 M $ au 31/07/2026
Fortune : 5 M $ au 31/07/2026
Julianne Bruno is currently an Independent Director at Damora Therapeutics, Inc. since 2025.
Formerly, Ms. Bruno was Chief Operating Officer at CRISPR Therapeutics AG from 2024 to 2025.
Education includes an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree from Princeton University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/04/2026 | 137 032 ( 0,22% ) | 4 M $ | 31/07/2026 | |
| 21/03/2025 | 17 632 ( 0,02% ) | 846 160 $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| DAMORA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 10/11/2025 |
| Sociétés | Poste | Fin |
|---|---|---|
| CRISPR THERAPEUTICS AG | Directeur des opérations | 11/04/2025 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CRISPR Therapeutics AG
CRISPR Therapeutics AG BiotechnologyHealth Technology Develops gene-based medicines | Health Technology |
Galecto, Inc.
Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national